

Incidence, Species Distribution, and Antifungal Susceptibility of *Candida* Bloodstream Infections in a Tertiary Algerian Hospital [†]

Assia Meradji ^{1,2,3,*}, Stéphane Ranque ⁴ , Fayza Bachtarzi ^{1,3}, Nabil Mosbah ⁵ and Tayeb Moulahem ^{1,2,3}

¹ Faculty of Medicine, University of Constantine 3 Salah Boubnider, Constantine 25000, Algeria; bachtarzi.fayza@gmail.com (F.B.)

² Laboratory of Biological and Pharmaceutical Sciences Applied to Health, Constantine 25000, Algeria

³ CHU Ben Badis, Constantine 25000, Algeria

⁴ IHU Méditerranée Infection, 13000 Marseille, France

⁵ CHU Saadna Abdenour Setif, Setif 19000, Algeria

* Correspondence: assia.meradji@yahoo.fr

[†] Presented at the 2nd International Electronic Conference on Microbiology, 1–15 December 2023; Available online: <https://ecm2023.sciforum.net/>.

Abstract: *Candida* infections are the most frequent invasive fungal diseases. To date, few studies have been conducted on candidemia in Algeria. The aim of this study was to assess the incidence, species distribution, and antifungal susceptibility for *Candida* bloodstream infections. This prospective, monocentric study covered all cases of candidemia diagnosed in the ICU at Setif hospital in Algeria. Yeast isolates were identified using MALDI TOF. Antifungal susceptibility testing was performed using Sensititre YeastOne. The incidence rate was 7.03 cases per admission in the ICU. Five *Candida* species were isolated: *C. albicans*, *C. glabrata*, *C. parapsilosis*, *C. tropicalis* and *C. pelliculosa*. Overall, 78.6% of isolates were sensitive to all antifungals.

Keywords: *Candida* spp.; candidemia; incidence; antifungals; resistance



Citation: Meradji, A.; Ranque, S.; Bachtarzi, F.; Mosbah, N.; Moulahem, T. Incidence, Species Distribution, and Antifungal Susceptibility of *Candida* Bloodstream Infections in a Tertiary Algerian Hospital. *Biol. Life Sci. Forum* **2024**, *31*, 30. <https://doi.org/10.3390/ECM2023-16684>

Academic Editor: Nico Jehmlich

Published: 26 December 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Candidemia is the most common invasive fungal infection among hospitalized patients. It is associated with a high rate of morbidity and mortality in hospitalized patients, especially those in intensive care units (ICUs) [1]. While this infection has been extensively studied in America, Europe, and Asia, it remains understudied in Algeria [2–4]. Recognizing variations in incidence, identifying high-risk populations, understanding species distribution, and assessing antifungal susceptibility patterns are crucial for establishing effective infection control measures and managing this disease. In order to gain a better understanding of this pathology in our region, a one-year prospective study was conducted at Sétif hospital in Algeria. The objective of this study was to determine the incidence, species distribution, and antifungal susceptibility of *Candida* bloodstream infections.

2. Materials and Methods

2.1. Study Design

This is a prospective study conducted over a one-year period, from October 2017 to November 2018, in the intensive care units of the University Hospital of Sétif in Algeria. Candidemia was defined as one positive blood culture for *Candida* species in clinically suspected ICU patients. Demographic characteristics were taken from the medical records.

2.2. Identification and Antifungal Susceptibility

Blood samples were incubated in a BacT/ALERT 480 system (bioMérieux, Marcy-l'Étoile, France). *Candida* species identification was performed at the time of diagnosis using several methods, including chromogenic agar media (*Candida* ID2; bioMérieux,

Table 1. Cont.

Species	Antifungal Agents	0.008	0.015	0.03	0.06	0.12	0.25	0.5	1	2	4	8	16
<i>C. parapsilosis</i> N = 3 (21.4%)	Fluconazole							2	1				
	Itraconazole			1	1	1							
	Voriconazole		1	2									
	Posaconazole				3								
	Amphotericin B							3					
	5 Fluorocytosine				3								
	Caspofungin							3					
	Micafungin								1	2			
	Anidulafungin								1	2			
Other Species N = 2 (14.3%)	Fluconazole								1			1	
	Itraconazole								2 [®]				
	Voriconazole					2							
	Posaconazole					1	1						
	Amphotericin B								2				
	5 Fluorocytosine				1	1							
	Caspofungin			1		1							
	Micafungin			2									
Anidulafungin		1		1									

I: intermediate, ®: resistant.

4. Discussion

The incidence of candidemia found in this study is consistent with reports from India (6.51 cases per 1000 admissions in ICUs) and France (6.9 cases per 1000 admissions in ICUs) [6,7]. Conversely, the incidence is much lower than that reported by a study conducted in thirty-two hospitals in Spain, three in Argentina, and one in France (34.3 cases per 1000 admissions) [8]. Studies conducted in Germany, Turkey, Denmark, and Egypt reported rates of 0.29, 1.76, 0.34, and 3.3 cases per 1000 ICU admission respectively [9–12].

According to the results of our study, 57% of the patients with candidemia were male. Invasive candidiasis, specifically candidemia, is less common in women than in men. This male predominance aligns with findings from several candidemia studies [12–14].

In our study, the age of patients varied from 44 days to 71 years, with an average age of 30,82 years. This observation is consistent with the findings of a Moroccan study, and another conducted in Latin America, where the average ages of patients were 27 and 26 years, respectively [15,16]. Similar data have been reported in other studies conducted in Turkey and Iran [17,18]. However, in many studies on candidemia conducted in North America, Europe, and some Asian countries, the average age falls between 50 and 69 years. In these countries, candidemia is linked not only to an increased number of immunocompromised patients but also to an aging population. Indeed, elderly patients exhibit numerous cumulative risk factors [4,19–21].

C. albicans was the most frequently identified species, accounting for 42.9% of isolated strains, followed by *C. parapsilosis* and *C. glabrata*. Similar findings have been reported in many studies, with a growing trend of candidemia caused by non-albicans species [22,23]. However, variations exist within these species prevalences. In the United States and many European countries, *C. glabrata* is the most common non-albicans species, comprising one-third or more of all candidemia isolates, while *C. parapsilosis* is generally the second most prevalent [11,24–26]. Conversely, Spain, Italy, Croatia, some regions of France,

Turkey, and Greece have reported a predominance of *C. parapsilosis* among non-*albicans* species [17,21,27,28]. In Africa and Latin America, the situation varies, with *C. albicans*, *C. parapsilosis*, and *C. tropicalis* being the predominant species. For example, in Brazil, *C. albicans* is the most common, followed by *C. parapsilosis* and *C. tropicalis* [29]. In Chile, it is *C. parapsilosis* followed by *C. glabrata* [22]. South Africa shows differences based on hospital type, with *C. albicans* prevailing in public hospitals and *C. parapsilosis* in private sector hospitals [30]. Algiers's Mustapha hospital found *C. parapsilosis* to be the most isolated species [31]. Egypt reported *C. krusei* as the most frequent species [12]. In Asia, a study in the Asia–Pacific region found *C. albicans* to be the most common, with *C. tropicalis* as the second most prevalent [32]. Similar results were found in Korea [33]. India have *C. tropicalis* as the most prevalent species [6]. According to Jesus Guinea, the reasons behind the global distribution of *Candida* species remain poorly understood. Various factors, including climate, antifungal use in hospitals, and regional patient microbiota, may influence species presence [27].

All *Candida* species in our study exhibited low MICs (minimal inhibitory concentrations) to amphotericin B ($\text{MIC} \leq 1 \mu\text{g}/\text{mL}$), reinforcing the reliability of this molecule as an empirical choice. While amphotericin B is no longer recommended as the first-line treatment for candidemia in several countries due to the introduction of new antifungals with a more favorable tolerance profile, it still serves as a therapeutic alternative, especially for isolates resistant to azoles and/or echinocandins. However, acquired resistance to amphotericin B remains rare [2,34]. The impact of prior prescriptions of this molecule on the MICs levels of *Candida* spp. has been demonstrated [35].

In our study, all azoles were effective against *C. albicans*. However, certain *Candida* species exhibited resistances to specific azole antifungals. Notably, there has been an increasing trend in recent years of resistance among *Candida* species, particularly towards fluconazole, in various countries around the world. Previous studies conducted in Europe, South America, and the United States reported low rates of resistance to fluconazole and itraconazole before 2005 [36]. However, data from the latter half of the decade revealed an emergence of resistance among nosocomial isolates, not only to azoles but also to echinocandins [37]. The use of azoles for curative or prophylactic purposes has been linked to the selection of less sensitive or resistant species, such as *C. krusei* and *C. glabrata*, as well as the development of resistance in initially susceptible strains, through the mutation and/or activation of efflux pumps [38].

While all our isolates were sensitive to echinocandins, caspofungin has only recently become available in Algeria, and micafungin and anidulafungin are not marketed. Selection pressures on naturally less sensitive strains like *C. parapsilosis* or even de novo acquisition of resistance through gene mutation (FKS) could play a role in the future as the use of echinocandins increases [39,40]. However, reports from certain parts of the world indicate resistance among nosocomial isolates, especially in *C. glabrata*, to echinocandins [2,41,42]. Due to their fungicidal properties against *Candida* species, including those with reduced susceptibility to azole drugs like *C. glabrata* and *C. krusei*, as well as their activity against fungal biofilms, echinocandins are now recommended as first-line treatment.

5. Conclusions

In conclusion, *C. albicans* was the most frequently isolated species in candidemia episodes, and most species were susceptible to antifungals. However, these findings warrant confirmation with larger cohorts. Indeed, most studies on candidemia are multicenter and retrospective, as this type of infection is less frequent and typically involves some high-risk services.

Author Contributions: Conceptualization, A.M. and T.M.; methodology, A.M., T.M., N.M. and S.R.; software, A.M. and F.B.; validation, A.M., S.R. and T.M.; formal analysis, A.M.; investigation, A.M.; resources, S.R. and T.M.; data curation, A.M.; writing—original draft preparation, A.M.; writing—review and editing, A.M. and T.M.; visualization, A.M.; supervision, T.M.; project adminis-

tration, T.M.; funding acquisition, T.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study design was reviewed and approved by the research Ethics committee of the University Hospital of Sétif, Saadna Abdennour, Algeria.

Informed Consent Statement: Informed consent was waived as the data were anonymized.

Data Availability Statement: Data are contained within the article.

Conflicts of Interest: The authors declare no conflicts of interest.

References

- Goemaere, B.; Becker, P.; Van Wijngaerden, E.; Maertens, J.; Spriet, I.; Hendrickx, M.; Lagrou, K. Increasing candidaemia incidence from 2004 to 2015 with a shift in epidemiology in patients preexposed to antifungals. *Mycoses* **2018**, *61*, 127–133. [CrossRef] [PubMed]
- Toda, M.; Williams, S.R.; Berkow, E.L.; Farley, M.M.; Harrison, L.H.; Bonner, L.; Marceaux, K.M.; Hollick, R.; Zhang, A.Y.; Schaffner, W.; et al. Population-Based Active Surveillance for Culture-Confirmed Candidemia—Four Sites, United States, 2012–2016. *MMWR* **2019**, *68*, 1–15. [CrossRef] [PubMed]
- O’Leary, R.A.; Einav, S.; Leone, M.; Madach, K.; Martin, C.; Martin-Loeches, I. Management of invasive candidiasis and candidaemia in critically ill adults: Expert opinion of the European Society of Anaesthesia Intensive Care Scientific Subcommittee. *J. Hosp. Infect.* **2018**, *98*, 382–390. [CrossRef] [PubMed]
- Xiao, Z.; Wang, Q.; Zhu, F.; An, Y. Epidemiology, species distribution, antifungal susceptibility and mortality risk factors of candidemia among critically ill patients: A retrospective study from 2011 to 2017 in a teaching hospital in China. *Antimicrob. Resist. Infect. Control* **2019**, *8*, 89. [CrossRef] [PubMed]
- Clinical and Laboratory Standards Institute. (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast; Fourth Informational Supplement. Wayne: Clinical and Laboratory Standards Institute; 2012. (Document M27-S4). Available online: https://clsi.org/media/1897/m27ed4_sample.pdf (accessed on 2 November 2023).
- Chakrabarti, A.; Sood, P.; Rudramurthy, S.M.; Chen, S.; Kaur, H.; Capoor, M.; Chhina, D.; Rao, R.; Eshwara, V.K.; Xess, I.; et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. *Intensive Care Med.* **2015**, *41*, 285–295. [CrossRef] [PubMed]
- Charlotte Renaudat, K.S.; Desnos-Ollivier, M.; Fontanet, A.; Bretagne, S.; Lortholary, O. Candidémies en Île-de-France: Données de l’Observatoire des levures (2002–2010). *Bull. Épidémiologique Hebd.* **2013**, *12–13*, 125–128.
- González de Molina, F.J.; León, C.; Ruiz-Santana, S.; Saavedra, P.; Group, C.I.S. Assessment of candidemia-attributable mortality in critically ill patients using propensity score matching analysis. *Crit. Care* **2012**, *16*, R105. [CrossRef] [PubMed]
- Meyer, E.; Geffers, C.; Gastmeier, P.; Schwab, F. No increase in primary nosocomial candidemia in 682 German intensive care units during 2006 to 2011. *Euro Surveill. Bull. Eur. Sur Les Mal. Transm. Eur. Commun. Dis. Bull.* **2013**, *18*, 1–8. [CrossRef]
- Tigen, E.T.; Bilgin, H.; Gurun, H.P.; Dogru, A.; Ozben, B.; Cerikcioglu, N.; Kortten, V. Risk factors, characteristics, and outcomes of candidemia in an adult intensive care unit in Turkey. *Am. J. Infect. Control* **2017**, *45*, e61–e63. [CrossRef]
- Risum, M.; Astvad, K.; Johansen, H.K.; Schønheyder, H.C.; Rosenvinge, F.; Knudsen, J.D.; Hare, R.K.; Datcu, R.; Røder, B.L.; Antsupova, V.S.; et al. Update 2016–2018 of the Nationwide Danish Fungaemia Surveillance Study: Epidemiologic Changes in a 15-Year Perspective. *J. Fungi* **2021**, *7*, 491. [CrossRef]
- Abass, E.; Mohamed, S.; El-Kholy, I.; Zaki, S. Incidence of ICU-Acquired Candidemia in a Tertiary Care Hospital in Cairo, Egypt. *Egypt. J. Microbiol.* **2019**, *54*, 55–61. [CrossRef]
- Routsi, C.; Meletiadis, J.; Charitidou, E.; Gkoufa, A.; Kokkoris, S.; Karageorgiou, S.; Giannopoulos, C.; Koulenti, D.; Andriko-giannopoulos, P.; Perivolioti, E.; et al. Epidemiology of Candidemia and Fluconazole Resistance in an ICU before and during the COVID-19 Pandemic Era. *Antibiotics* **2022**, *11*, 771. [CrossRef]
- Macauley, P.; Epelbaum, O. Epidemiology and Mycology of Candidaemia in non-oncological medical intensive care unit patients in a tertiary center in the United States: Overall analysis and comparison between non-COVID-19 and COVID-19 cases. *Mycoses* **2021**, *64*, 634–640. [CrossRef]
- Abid, R.; El Mabrouki, J.; Soussi Abdallaoui, M. Les candidémies au CHU Ibn Rochd de Casablanca (Maroc). *J. De Mycol. Médicale* **2017**, *27*, e26. [CrossRef]
- Nucci, M.; Queiroz-Telles, F.; Alvarado-Matute, T.; Tiraboschi, I.N.; Cortes, J.; Zurita, J.; Guzman-Blanco, M.; Santolaya, M.E.; Thompson, L.; Sifuentes-Osornio, J.; et al. Epidemiology of candidemia in Latin America: A laboratory-based survey. *PLoS ONE* **2013**, *8*, e59373. [CrossRef]
- Ulu Kilic, A.; Alp, E.; Cevahir, F.; Ture, Z.; Yozgat, N. Epidemiology and cost implications of candidemia, a 6-year analysis from a developing country. *Mycoses* **2017**, *60*, 198–203. [CrossRef]

18. Vaezi, A.; Fakhim, H.; Khodavaisy, S.; Alizadeh, A.; Nazeri, M.; Soleimani, A.; Boekhout, T.; Badali, H. Epidemiological and mycological characteristics of candidemia in Iran: A systematic review and meta-analysis. *J. De Mycol. Médicale J. Med. Mycol.* **2017**, *27*, 146–152. [[CrossRef](#)] [[PubMed](#)]
19. Mellinghoff, S.C.; Hartmann, P.; Cornely, F.B.; Knauth, L.; Kohler, F.; Kohler, P.; Krause, C.; Kronenberg, C.; Kranz, S.L.; Menon, V.; et al. Analyzing candidemia guideline adherence identifies opportunities for antifungal stewardship. *Eur. J. Clin. Microbiol. Infect. Dis.* **2018**, *37*, 1563–1571. [[CrossRef](#)] [[PubMed](#)]
20. Tadec, L.; Talarmin, J.P.; Gastinne, T.; Bretonniere, C.; Miegerville, M.; Le Pape, P.; Morio, F. Epidemiology, risk factor, species distribution, antifungal resistance and outcome of Candidemia at a single French hospital: A 7-year study. *Mycoses* **2016**, *59*, 296–303. [[CrossRef](#)] [[PubMed](#)]
21. Bassetti, M.; Merelli, M.; Righi, E.; Diaz-Martin, A.; Rosello, E.M.; Luzzati, R.; Parra, A.; Trecarichi, E.M.; Sanguinetti, M.; Posteraro, B.; et al. Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. *J. Clin. Microbiol.* **2013**, *51*, 4167–4172. [[CrossRef](#)] [[PubMed](#)]
22. Santolaya, M.E.; Thompson, L.; Benadof, D.; Tapia, C.; Legarraga, P.; Cortés, C.; Rabello, M.; Valenzuela, R.; Rojas, P.; Rabagliati, R. A prospective, multi-center study of *Candida* bloodstream infections in Chile. *PLoS ONE* **2019**, *14*, e0212924. [[CrossRef](#)] [[PubMed](#)]
23. Alobaid, K.; Ahmad, S.; Asadzadeh, M.; Mokaddas, E.; Al-Sweih, N.; Albenwan, K.; Alfouzan, W.; Al-Obaid, I.; Jeragh, A.; Al-Roomi, E.; et al. Epidemiology of Candidemia in Kuwait: A Nationwide, Population-Based Study. *J. Fungi* **2021**, *7*, 673. [[CrossRef](#)] [[PubMed](#)]
24. Trouve, C.; Blot, S.; Hayette, M.P.; Jonckheere, S.; Patteet, S.; Rodriguez-Villalobos, H.; Symoens, F.; Van Wijngaerden, E.; Lagrou, K. Epidemiology and reporting of candidaemia in Belgium: A multi-centre study. *Eur. J. Clin. Microbiol. Infect. Dis.* **2017**, *36*, 649–655. [[CrossRef](#)] [[PubMed](#)]
25. Pfaller, M.A.; Diekema, D.J.; Turnidge, J.D.; Castanheira, M.; Jones, R.N. Twenty Years of the SENTRY Antifungal Surveillance Program: Results for *Candida* Species from 1997–2016. *Open Forum Infect. Dis.* **2019**, *6*, S79–S94. [[CrossRef](#)] [[PubMed](#)]
26. Adam, K.-M.; Osthoff, M.; Lamoth, F.; Conen, A.; Erard, V.; Boggian, K.; Schreiber, P.W.; Zimmerli, S.; Bochud, P.-Y.; Neofytos, D.; et al. Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey. *Open Forum Infect. Dis.* **2021**, *8*, ofab471. [[CrossRef](#)]
27. Guinea, J.; Zaragoza, O.; Escribano, P.; Martin-Mazuelos, E.; Peman, J.; Sanchez-Reus, F.; Cuenca-Estrella, M. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. *Antimicrob. Agents Chemother.* **2014**, *58*, 1529–1537. [[CrossRef](#)]
28. Mamali, V.; Siopi, M.; Charpantidis, S.; Samonis, G.; Tsakris, A.; Vrioni, G.; Candi-Candi Network. Increasing Incidence and Shifting Epidemiology of Candidemia in Greece: Results from the First Nationwide 10-Year Survey. *J. Fungi* **2022**, *8*, 116. [[CrossRef](#)]
29. Doi, A.M.; Pignatari, A.C.; Edmond, M.B.; Marra, A.R.; Camargo, L.F.; Siqueira, R.A.; da Mota, V.P.; Colombo, A.L. Epidemiology and Microbiologic Characterization of Nosocomial Candidemia from a Brazilian National Surveillance Program. *PLoS ONE* **2016**, *11*, e0146909. [[CrossRef](#)]
30. Govender, N.P.; Patel, J.; Magobo, R.E.; Naicker, S.; Wadula, J.; Whitelaw, A.; Coovadia, Y.; Kularatne, R.; Govind, C.; Lockhart, S.R.; et al. Emergence of azole-resistant *Candida parapsilosis* causing bloodstream infection: Results from laboratory-based sentinel surveillance in South Africa. *J. Antimicrob. Chemother.* **2016**, *71*, 1994–2004. [[CrossRef](#)]
31. Arrache, D.; Madani, K.; Zait, H.; Achir, I.; Younsi, N.; Zebdi, A.; Bouahri, L.; Chaouche, F.; Hamrioui, B. Fongémies diagnostiquées au laboratoire de parasitologie-mycologie du CHU Mustapha d’Alger, Algérie (2004–2014). *J. De Mycol. Médicale* **2015**, *25*, 237–238. [[CrossRef](#)]
32. Tan, T.Y.; Hsu, L.Y.; Alejandria, M.M.; Chaiwarith, R.; Chinniah, T.; Chayakulkeeree, M.; Choudhury, S.; Chen, Y.H.; Shin, J.H.; Kiratisin, P.; et al. Antifungal susceptibility of invasive *Candida* bloodstream isolates from the Asia-Pacific region. *Med. Mycol.* **2016**, *54*, 471–477. [[CrossRef](#)]
33. Kim, E.J.; Lee, E.; Kwak, Y.G.; Yoo, H.M.; Choi, J.Y.; Kim, S.R.; Shin, M.J.; Yoo, S.-Y.; Cho, N.-H.; Choi, Y.H. Trends in the Epidemiology of Candidemia in Intensive Care Units From 2006 to 2017: Results From the Korean National Healthcare-Associated Infections Surveillance System. *Front. Med.* **2020**, *7*, 606976. [[CrossRef](#)] [[PubMed](#)]
34. Klepser, M. The value of amphotericin B in the treatment of invasive fungal infections. *J. Crit. Care* **2011**, *26*, 225.e1–225.e10. [[CrossRef](#)] [[PubMed](#)]
35. Fournier, P.; Schwebel, C.; Maubon, D.; Vesin, A.; Lebeau, B.; Foroni, L.; Hamidfar-Roy, R.; Cornet, M.; Timsit, J.F.; Pelloux, H. Antifungal use influences *Candida* species distribution and susceptibility in the intensive care unit. *J. Antimicrob. Chemother.* **2011**, *66*, 2880–2886. [[CrossRef](#)] [[PubMed](#)]
36. Pfaller, M.A.; Diekema, D.J. Epidemiology of invasive candidiasis: A persistent public health problem. *Clin. Microbiol. Rev.* **2007**, *20*, 133–163. [[CrossRef](#)]
37. Pfaller, M.A.; Moet, G.J.; Messer, S.A.; Jones, R.N.; Castanheira, M. *Candida* bloodstream infections: Comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008–2009. *Antimicrob. Agents Chemother.* **2011**, *55*, 561–566. [[CrossRef](#)] [[PubMed](#)]
38. Sobel, J.D.; Akins, R. The role of resistance in *Candida* infections: Epidemiology and treatment. In *Antimicrobial Drug Resistance*; Springer: Berlin/Heidelberg, Germany, 2017; pp. 1075–1097.

39. Lortholary, O.; Desnos-Ollivier, M.; Sitbon, K.; Fontanet, A.; Bretagne, S.; Dromer, F. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: A prospective multicenter study involving 2441 patients. *Antimicrob. Agents Chemother.* **2011**, *55*, 532–538. [[CrossRef](#)] [[PubMed](#)]
40. Dannaoui, E.; Desnos-Ollivier, M.; Garcia-Hermoso, D.; Grenouillet, F.; Cassaing, S.; Baixench, M.T.; Bretagne, S.; Dromer, F.; Lortholary, O. *Candida* spp. with acquired echinocandin resistance, France, 2004–2010. *Emerg. Infect. Dis.* **2012**, *18*, 86–90. [[CrossRef](#)]
41. Lewis, J.S., II; Wiederhold, N.P.; Wickes, B.L.; Patterson, T.F.; Jorgensen, J.H. Rapid emergence of echinocandin resistance in *Candida glabrata* resulting in clinical and microbiologic failure. *Antimicrob. Agents Chemother.* **2013**, *57*, 4559–4561. [[CrossRef](#)]
42. Vallabhaneni, S.; Cleveland, A.; Farley, M.; Harrison, L.; Schaffner, W.; Beldavs, Z.; Derado, G.; Pham, C.; Lockhart, S.; Smith, R. Epidemiology and Risk Factors for Echinocandin Non susceptible *Candida glabrata* Bloodstream Infections: Data from a Large Multisite Population-Based Candidemia Surveillance Program, 2008–2014. *Open Forum Infect. Dis.* **2015**, *2*, ofv163. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.